• Arm targets $50-55 billion valuation for Nasdaq listing.
  • Amgen settles FTC challenge to Horizon Therapeutics acquisition.
  • Australian lithium producer Liontown Resources backs Albemarle's $4.3 billion bid.
  • Lloyds Banking Group is in talks with the Barclay family and US private equity firm Carlyle to acquire Very Group.
  • Novo Nordisk launches its weight-loss drug Wegovy in the UK.
  • BMW forecasts an increase in sales in China in 2023, according to its CFO.
  • Nestlé sells Palforzia, its peanut allergy treatment business, to Stallergenes Greer.
  • Novartis sues the US government over drug price regulation.
  • Cosmo Pharmaceuticals changes partner for Rifamycin SV MMX.
  • Flughafen Zürich confirms its medium- and long-term financial targets.
  • Hexatronic acquires New Zealand-based ATG Technology.
  • Italian government may accelerate sale of its stake in Banca Monte dei Paschi di Siena.
  • Encavis obtains a 180 million euro revolving credit facility.
  • London Stock Exchange Group to create new blockchain-based digital markets unit.